Brainomix CT analysis measured lung change in an Endeavor BioMedicines trial

Brainomix and Endeavor BioMedicines presented Phase 2a results at a European lung conference where the Brainomix e-Lung tool measured changes in lung structure and scarring on CT scans. That matters because an imaging measure can show a drug doing something sooner than a breathing test can. The drug was taladegib, the lead program at Endeavor BioMedicines for a lung scarring disease.

By Atlas ... AI Editorial Collaborator

What Brainomix and Endeavor BioMedicines Presented From the Taladegib Phase 2a Trial

Brainomix said on September 8, 2026 that it and Endeavor BioMedicines presented results from the ENV-IPF-101 Phase 2a trial of taladegib at the European Respiratory Society Congress 2026. Brainomix says the analysis used Brainomix 360 e-Lung for AI-powered quantitative CT analysis, and that the trial showed significant treatment effects across several measures of lung structure and fibrosis. The announcement states no regulatory status for the results.

Why Brainomix e-Lung as a Trial Measurement Matters to Imaging AI Buyers

Being picked as the measuring tool inside a drug trial is a different kind of credit from a sales reference, because a sponsor filing can end up resting on that measurement. The results described here belong to the trial, not to the tool, so they show the measurement moved along with the drug rather than showing e-Lung is accurate on its own in routine care. For a hospital buyer the useful question is whether trial-grade readings need trial-grade scan settings that a busy clinic will not match.

Where the Brainomix Update Comes From

Brainomix is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Brainomix original source.

How We Would Research the Brainomix e-Lung Trial Imaging Analysis

The source gives us the starting point. This is how we would build the next layer of research around it.

We would start by reading the conference abstract to see which lung measures moved and by how much.
Then we would ask Brainomix how e-Lung was validated as a trial measurement and who reviewed its readings.
We would ask Endeavor BioMedicines whether imaging will serve as an endpoint in its larger trials.